Key points from article :
Oisín Biotechnologies is a privately held, preclinical biotechnology company.
Oisín is developing a highly precise, DNA-based intervention to clear senescent cells in the body.
Made it to MIT Technology Review’s TR10 list of the Top 10 Breakthrough Technologies of 2020.
TR10 list recognized Oisín as a key player in the development of anti-aging therapeutics.
Has the potential to impact medicine on a time horizon shorter than five years.
Has closed a $3 million pre-seed SAFE funding round to further company’s research and development.
